GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
Go back to GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy| GammaCan International, Inc. (AMEX: GCAN) | Delayed: 0.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.37 | 52 Week High | $0.01 | |||
| Open | $0.37 | 52 Week Low | $0.00 | |||
| Day High | $0.37 | P/E | N/A | |||
| Day Low | $0.37 | EPS | $0.00 | |||
| Volume | 3 | |||||
